Health Affairs, 26, no. 3 (2007): 863-870 doi: 10.1377/hlthaff.26.3.863 © 2007 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Davis, J. J. Search for Related Content PubMed Articles by Davis, J. J. Related Collections Pharmaceuticals Consumer Issues

DataWatch

Consumers’ Preferences For The Communication Of Risk Information In Drug Advertising

Research was conducted to identify consumers’ preferences regarding the form, content, and placement of drug side-effect information in direct-to-consumer (DTC) advertising. Specific questions explored preferences for the presence or absence of numeric information, the use of placebo and discontinuation groups as a context for understanding drug risk, the sequence in which side effects are presented, and the placement of side-effect statements on DTC Web sites. Consumers prefer detailed, readily accessible risk information—preferences that are a major departure from current advertiser practices and from what current and proposed Food and Drug Administration (FDA) regulations require.

                      What's this?

This article has been cited by other articles:

				L. M. Schwartz, S. Woloshin, and H. G. Welch Using a Drug Facts Box to Communicate Drug Benefits and Harms: Two Randomized Trials Ann Intern Med, April 21, 2009; 150(8): 516 - 527. [Abstract] [Full Text] [PDF]